Adia Nutrition, Inc. (ADIA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00687W1099
Adia Nutrition, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 700,508.00 USD |
| Gross profit | 191,670.00 USD |
| Operating income | -366,492.00 USD |
| EBIT | -363,867.00 USD |
| Net income | -395,464.00 USD |
| Diluted EPS – continuing operations | 0.00 USD |
Full history since 2002, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Adia Nutrition, Inc.
Adia Med Inc operates as a clinical-stage regenerative medicine company. The company offers products and services focused on stem cell therapies, regenerative medicine treatments, and clinical research in areas such as aesthetics, orthopedics, and autoimmune diseases. In addition, the company offers nutritional supplements and biologic products. It sells its products on a direct-to-consumer basis, as well as through other direct to consumer channels. The company was formerly known as Adia Nutrition, Inc. and changed its name to Adia Med Inc in June 2026. Adia Med Inc is based in Winter Park, Florida.
More stocks
- IRIDEX CORP (IRIX)
- BIOVIE INC. (BIVI)
- Tele Columbus (TC1.HM)
- FGI Industries Ltd. (FGI)
- Magnolia Bancorp, Inc. (MGNO)
- FRACTYL HEALTH, INC. (GUTS)
- MANNATECH INC (MTEX)
- AQUABOUNTY TECHNOLOGIES INC (AQB)
- BLOOMIA HOLDINGS, INC. (TULP)
- Awaysis Capital, Inc. (AWCA)
- KIDOZ INC. (KDOZF)
- Aspire Biopharma Holdings, Inc. (ASBP)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.